Lloyd-Evans S, Brocklehurst J C, Palmer M K
Curr Med Res Opin. 1979;6(5):351-7. doi: 10.1185/03007997909109450.
A double-blind, placebo-controlled trial was carried out on 109 aged patients with minimal or with moderate chronic brain failure to assess the effectiveness of piracetam (2.4 g per day) in preventing the progression of dementia. Patients received piracetam or placebo each for 6 weeks, the order of treatment being at random. The results of 19 psychological tests, repeated at 6-weekly intervals, showed that piracetam produced statistically significant improvement in only one of them and then only during the first 6 weeks of treatment. These findings, therefore, do not support the usefulness of piracetam in the treatment of such patients.
对109例轻度或中度慢性脑功能衰竭的老年患者进行了一项双盲、安慰剂对照试验，以评估吡拉西坦（每日2.4克）预防痴呆进展的有效性。患者随机接受吡拉西坦或安慰剂治疗，各治疗6周。每6周重复进行19项心理测试，结果显示吡拉西坦仅在其中一项测试中产生了具有统计学意义的改善，且仅在治疗的前6周出现。因此，这些研究结果不支持吡拉西坦用于治疗此类患者。
